Report
EUR 13.77 For Business Accounts Only

A double requalification allows INNOVIVA to improve to Slightly Positive

INNOVIVA (US), a company active in the Pharmaceuticals industry, has received a double requalification by the independent financial analyst theScreener. Its fundamental valuation is now 2 out of 4 stars while its market behaviour can be considered as defensive. theScreener believes that the gain of a star(s) and an improvement in the market risk perception allows upgrading the general evaluation to Slightly Positive. As of the analysis date March 19, 2021, the closing price was USD 12.26 and its potential was estimated at USD 14.30.
Underlying
Innoviva Inc.

Innoviva is a company with a portfolio of royalties that include respiratory assets. The company's Long-Acting Beta2 Agonist (LABA) collaboration has developed the combination products: RELVAR? /BREO? ELLIPTA?, a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS), fluticasone furoate (FF); ANORO? ELLIPTA?, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, VI; and RELEGY? ELLIPTA? (the combination FF/UMEC/VI), a once-daily combination medicine consisting of an ICS, LAMA and LABA.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch